αChemR23 antibody being able to activate human as well as mouse ChemR23 receptor (Figure S12), we further investigate the interest to target ChemR23 in cancers, we evaluated agonist anti-ChemR23 mAb treatment in vivo on BC progression using the orthotopic syngeneic triple-negative 4T1-luc2 model. This evidence concerns the gene CMKLR1 and cancer.